SEX-RELATED DIFFERENCE IN THE REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB: INSIGHTS FROM GLAGOV

E-resources

Peer reviewed Open access

SEX-RELATED DIFFERENCE IN THE REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB: INSIGHTS FROM GLAGOV

King, Peta; Puri, Rishi; Ballantyne, Christie; Cho, Leslie; Brennan, Danielle; Kassahun, Helina; Somaratne, Ransi; Wasserman, Scott; Nissen, Steven; Nicholls, Stephen

Journal of the American College of Cardiology, 03/2018, Volume: 71, Issue: 11

Journal Article

Methods GLAGOV compared the effects of treatment for 78 weeks with evolocumab or placebo on progression of coronary atherosclerosis, measured by serial intravascular ultrasonography, in statin-treated patients with coronary artery disease. Results Female patients were older (61.7 vs 58.8 years, P<0.001), more likely to have hypertension (89.2 vs 79.5%, P=0.001), two or more risk factors at baseline (77.2 vs 66.4%, P=0.003) and low HDL-C (females <50mg/dL, males <40mg/dL) at baseline (49.6 vs 39.1%, P=0.006).

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme